Settlements, Significant Study Results, and Product Launches Lead to Advancements in Patient Care - Research Report on GSK, Isis, Endo, Pacira, and Dr. Reddy's

NEW YORK, July 25, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting GlaxoSmithKline plc (NYSE: GSK), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Dr. Reddy's Laboratories Ltd. (NYSE: RDY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

GlaxoSmithKline plc Research Report

On July 22, 2013, GlaxoSmithKline plc (GSK) and GlaxoSmithKline Consumer Nigeria Plc. (GSK Nigeria) announced the withdrawal of the proposed arrangement under which the Company was to increase its indirect ownership in GSK Nigeria to 75%. GSK and GSK Nigeria believe that the suspension of the scheme of arrangement is necessary to consider appropriate amendments to the proposal for GSK to increase its indirect ownership in GSK Nigeria. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/GSK]

--

Isis Pharmaceuticals, Inc. Research Report

On July 22, 2013, Isis Pharmaceuticals, Inc. (Isis) announced data from Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. The study revealed that patients treated with ISIS-APOCIII Rx reported reductions of up to 70% in apolipoprotein C-III (apoC-III) and up to 64% in triglycerides. Isis further added that the treated patients witnessed an increase of upto 52% in high density lipoprotein cholesterol (the good cholesterol) and an up to 77% reduction in apoC-III associated very low density lipoprotein particles. Richard Geary, Ph.D., Senior Vice President of Development at Isis stated, "We look forward to sharing the results from our ongoing Phase 2 study evaluating ISIS-APOCIIIRx as a monotherapy in patients with severely high triglycerides. In this study, we hope to show that treatment with ISIS-APOCIIIRx in patients with severely high triglycerides also produces significant effects on apoC-III, triglycerides and HDL-C." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/ISIS]

--

Endo Pharmaceuticals Holdings Inc. Research Report

On July 22, 2013, Endo Health Solutions Inc. (Endo Health Solutions) announced the appointment of Don DeGolyer as Chief Operating Officer, Pharmaceuticals with effect from August 1, 2013. Rajiv De Silva, President and CEO of Endo Health Solutions, stated, "Don is a uniquely qualified, seasoned leader with nearly three decades of experience in the healthcare industry. Don has broad experience in both branded and generic pharmaceuticals and I have tremendous confidence in his ability to drive operational excellence and growth." According to the Company, Mr. DeGolyer previously served as President and CEO of Sandoz Inc., and spent 11 years at Johnson & Johnson in various roles including President of Marketing and Sales. The Full Research Report on Endo Pharmaceuticals Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/ENDP]

--

Pacira Pharmaceuticals Inc. Research Report

On July 18, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced results from the second IMPROVE study which assesses postsurgical opioid use and health economic outcomes between patients receiving EXPAREL as the foundation of an opioid-sparing multimodal regimen, versus a standard opioid-based analgesic regimen. Jorge E. Marcet, M.D., the study's Lead Author and Professor and Division Director of colon and rectal surgery at Morsani College of Medicine, University of South Florida, said, "In these patients, an opioid-sparing multimodal regimen using EXPAREL was shown to significantly reduce opioid intake, enable earlier discharge and lower the associated costs of care compared to a standard opioid-based pain management strategy". Dave Stack, President, CEO and Chairman of Pacira Pharmaceuticals, Inc. added, "The IMPROVE studies, which demonstrate measurable advantages when using an EXPAREL-based multimodal regimen compared to an opioid-based approach, may prompt a shift towards an opioid-sparing pain management model." The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/PCRX]

--

Dr. Reddy's Laboratories Ltd. Research Report

On July 12, 2013, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced that it has launched its Decitabine for Injection (50 mg) in the U.S. market on July 11, 2013, after the Company received approval from US Food & Drug Administration (FDA). According to the Company, the new launched product is a therapeutic equivalent generic version of Dacogen and is available as a single dose vial. According to IMS Health, the Dacogen brand generated U.S sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013. The Full Research Report on Dr. Reddy's Laboratories Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/RDY]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports